Abstract | BACKGROUND: METHODS: We retrospectively evaluated 544 HCT recipients with laboratory-confirmed PIV and classified LRTD into 3 groups: possible (PIV detection in upper respiratory tract with new pulmonary infiltrates with/without LRTD symptoms), probable (PIV detection in lung with LRTD symptoms without new pulmonary infiltrates), and proven (PIV detection in lung with new pulmonary infiltrates with/without LRTD symptoms). RESULTS: Probabilities of 90-day survival after LRTD were 87%, 58%, and 45% in possible, probable, and proven cases, respectively. Patients with probable and proven LRTD had significantly worse survival than those with upper respiratory tract infection (probable: hazard ratio [HR], 5.87 [P < .001]; proven: HR, 9.23 [P < .001]), whereas possible LRTD did not (HR, 1.49 [P = .27]). Among proven/probable cases, oxygen requirement at diagnosis, low monocyte counts, and high-dose steroid use (>2 mg/kg/day) were associated with high mortality in multivariable analysis. CONCLUSIONS: PIV LRTD with viral detection in lungs (proven/probable LRTD) was associated with worse outcomes than was PIV LRTD with viral detection in upper respiratory samples alone (possible LRTD). This new classification should impact clinical trial design and permit comparability of results among centers.
|
Authors | Sachiko Seo, Hu Xie, Angela P Campbell, Jane M Kuypers, Wendy M Leisenring, Janet A Englund, Michael Boeckh |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 58
Issue 10
Pg. 1357-68
(May 2014)
ISSN: 1537-6591 [Electronic] United States |
PMID | 24599766
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Steroids
|
Topics |
- Adult
- Antiviral Agents
(therapeutic use)
- Bronchoalveolar Lavage Fluid
(virology)
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Lung
(virology)
- Male
- Middle Aged
- Paramyxoviridae Infections
(classification, drug therapy, mortality, virology)
- Paramyxovirinae
(isolation & purification)
- Respiratory Insufficiency
(etiology)
- Respiratory Tract Infections
(classification, drug therapy, mortality, virology)
- Retrospective Studies
- Risk Factors
- Steroids
(administration & dosage)
- Survival Rate
- Viral Load
- Young Adult
|